Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

‘Trojan horse’ antibiotic shows promise
"Our results support cefiderocol as a novel approach that might be used to overcome Gram-negative resistance." (Stock photo)
Drug works by tricking bacteria in allowing it to enter 

A new antibiotic that acts like the Trojan horse in Greek legend has shown promise in phase two trials, scientists have said.

Cefiderocol works by tricking bacteria in allowing it to enter. It was found to be as effective as the current standard-of-care antibiotic, in the treatment of complicated urinary tract infections (UTIs) caused by several multi-drug-resistant Gram-negative bacteria.

Findings published in The Lancet Infectious Diseases journal suggest that patients treated with cefiderocol had a higher and more sustained level of pathogen eradication; and similar clinical outcomes to those treated with imipenem-cilastatin.

The study randomised 448 adults who had been hospitalised with a complicated UTI or uncomplicated pyelonephritis. Three hundred patients received three daily infusions of cefiderocol for seven to 10 days, while the remainder were given imipenem-cilastatin.

Seven days after treatment stopped, cefiderocol showed efficacy rates of 73 per cent and 55 per cent respectively for clinical and microbiological responses.

Lead author Dr Simon Portsmouth, from Shionogi Inc, said: "Cefiderocol was found to be both safe and tolerable in a population of older patients who were very ill with complex comorbid conditions and a wide range of multidrug-resistant pathogens. Our results support cefiderocol as a novel approach that might be used to overcome Gram-negative resistance.

"Ongoing clinical trials of pneumonia, including hospital-acquired pneumonia and ventilator-associated pneumonia, and a study in patients with carbapenem-resistant infections, will provide additional important information about cefiderocol."

Become a member or log in to add this story to your CPD history

Nominations open for Blue Cross Medal 2019

News Story 1
 Animal lovers are being urged to nominate their pet heroes for the Blue Cross Medal 2019.

Celebrating inspirational pets for almost 80 years, the Award is open to pets that have done something brave, life-changing partnerships, assistance animals and serving or working animals.

To find out more about the awards and to nominate a pet, visit The closing date for entries is 15 February 2019.  

Click here for more...
News Shorts
Northampton graduate wins industry award

A graphic communications graduate from the University of Northampton has won an industry award for her campaign to persuade people to choose a rescue dog over a puppy.

Taylar Wong received a YCN Student Award for her concept, which likened a rescue dog’s stay at the Dogs Trust to a time at University. Injecting some fun into the adoption process, Taylor produced images of cute dogs wearing mortarboards for use on social media and physical advertising.